AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa and ...
A therapy for Parkinson’s disease that can be delivered by a 24-hour subcutaneous infusion pump has been recommended for use by the NHS and could be an option for hundreds of patients with the ...
Sterkt fremskreden Parkinsons sykdom er preget av komplikasjoner, spesielt fluktuerende motorisk funksjon, som er vanskelige å kontrollere med tradisjonell peroral medisinering. Vi presenterer vår ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results